1. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
- Author
-
Alexis J. Combes, Santiago Zelenay, Christian P. Bromley, Matthew F. Krummel, Ignacio Melero, Paola Brandi, Alfonso R. Sánchez-Paulete, Carlos del Fresno, Manuel Gómez, Elena Hernández-García, Francisco J. Cueto, Michel Enamorado, Ruth Conde-Garrosa, Salvador Iborra, David Sancho, Santos Mañes, Fundación La Caixa, Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, NIHR - Manchester Biomedical Research Centre (Reino Unido), European Research Council, Unión Europea. Comisión Europea, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Comunidad de Madrid (España), Fondation ACTERIA (Acting on European Research in Immunology and Allergology), Atresmedia, Fundación La Marató TV3, Fundación ProCNIC, and Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)
- Subjects
0301 basic medicine ,DNGR-1/Clec9a ,Cancer Research ,maraviroc ,Skin Neoplasms ,Genetic enhancement ,medicine.medical_treatment ,Melanoma, Experimental ,CD8-Positive T-Lymphocytes ,Inbred C57BL ,immunomodulation ,Mice ,0302 clinical medicine ,Immunologic ,Lectins ,Receptors ,Tumor Microenvironment ,Immunology and Allergy ,cDC1 ,Lymphocytes ,Receptors, Immunologic ,Melanoma ,Chemokine CCL5 ,Ensure healthy lives and promote well-being for all at all ages ,RC254-282 ,Cancer ,Mice, Knockout ,Tumor ,C-Type ,biology ,CCL5 ,Manchester Cancer Research Centre ,Flt3L ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,Tumor Burden ,Gene Expression Regulation, Neoplastic ,Basic-Leucine Zipper Transcription Factors ,Phenotype ,Oncology ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Molecular Medicine ,immunotherapy ,Antibody ,Signal Transduction ,Receptors, CCR5 ,Knockout ,Immunology ,Cell Line ,Experimental ,03 medical and health sciences ,Immune system ,Lymphocytes, Tumor-Infiltrating ,Antigen ,Cell Line, Tumor ,Genetics ,medicine ,Animals ,Lectins, C-Type ,Tumor-Infiltrating ,dendritic cells ,Pharmacology ,Neoplastic ,Tumor microenvironment ,ResearchInstitutes_Networks_Beacons/mcrc ,Membrane Proteins ,Basic Tumor Immunology ,Immunotherapy ,Genetic Therapy ,Dendritic Cells ,Coculture Techniques ,DNGR-1 ,Mice, Inbred C57BL ,Repressor Proteins ,030104 developmental biology ,Gene Expression Regulation ,Clec9a ,Cancer research ,biology.protein ,Tumor Escape ,CCR5 ,CD8 - Abstract
Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in antitumor immunity has not been clarified yet.
- Published
- 2021
- Full Text
- View/download PDF